Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Sell Rating

Hoth Therapeutics (NASDAQ:HOTH) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

A number of other analysts have also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research report on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Hoth Therapeutics has an average rating of “Hold” and a consensus price target of $5.00.

Hoth Therapeutics Stock Performance

HOTH opened at $0.99 on Friday. The firm’s fifty day moving average is $1.00 and its two-hundred day moving average is $1.23. The firm has a market cap of $15.40 million, a PE ratio of -0.94 and a beta of 0.50. Hoth Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.12.

Institutional Trading of Hoth Therapeutics

A number of hedge funds have recently modified their holdings of the stock. DRW Securities LLC bought a new position in Hoth Therapeutics in the 4th quarter valued at about $257,000. Citadel Advisors LLC bought a new stake in shares of Hoth Therapeutics during the third quarter worth approximately $232,000. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics during the third quarter worth approximately $184,000. Geode Capital Management LLC grew its position in shares of Hoth Therapeutics by 18.0% in the fourth quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock valued at $179,000 after purchasing an additional 27,577 shares during the last quarter. Finally, Kestra Private Wealth Services LLC bought a new position in shares of Hoth Therapeutics during the third quarter worth approximately $51,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.